Heartflow (NASDAQ:HTFL) Issues Earnings Results, Misses Expectations By $1.26 EPS

Key Points

• Heartflow reported a quarterly earnings loss of ($1.46) per share, significantly missing the consensus estimate of ($0.20) by ($1.26).
• Following the earnings announcement, shares of Heartflow (HTFL) increased by 1.2%, closing at $32.88, with a trading volume of 1,486,218 shares.
• Multiple analysts have initiated coverage on Heartflow, with average price targets ranging from $35.00 to $38.00 and a consensus rating of "Moderate Buy."

Heartflow (NASDAQ:HTFL - Get Free Report) posted its quarterly earnings results on Friday. The company reported ($1.46) EPS for the quarter, missing the consensus estimate of ($0.20) by ($1.26), Zacks reports. The business had revenue of $43.42 million for the quarter, compared to the consensus estimate of $43.20 million.

Heartflow Stock Down 4.4%

Shares of HTFL traded down $1.45 during midday trading on Monday, reaching $31.43. The company had a trading volume of 257,555 shares, compared to its average volume of 383,364. Heartflow has a 1-year low of $26.56 and a 1-year high of $36.68.

Analyst Ratings Changes

HTFL has been the subject of several analyst reports. JPMorgan Chase & Co. began coverage on shares of Heartflow in a report on Tuesday, September 2nd. They set an "overweight" rating and a $36.00 price target for the company. Morgan Stanley began coverage on Heartflow in a research report on Tuesday, September 2nd. They issued an "equal weight" rating and a $35.00 price target on the stock. Canaccord Genuity Group boosted their price objective on Heartflow from $35.00 to $39.00 and gave the stock a "buy" rating in a report on Monday. Stifel Nicolaus started coverage on shares of Heartflow in a report on Tuesday, September 2nd. They set a "buy" rating and a $35.00 target price on the stock. Finally, Piper Sandler initiated coverage on shares of Heartflow in a research report on Tuesday, September 2nd. They set an "overweight" rating and a $38.00 price objective for the company. Four investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $36.60.

Heartflow Company Profile

We have pioneered the use of software and AI to deliver a more accurate and clinically effective non-invasive solution for diagnosing and managing coronary artery disease (“CAD”), a leading cause of death worldwide. As of March 31, 2025, our Heartflow Platform has been used to assess CAD in more than 400,000 patients, including 132,000 in 2024 alone.